Cytogam®

Understanding Cytogam®
Cytogam® (cytomegalovirus immune globulin intravenous [human]) is approved by the U.S. FDA for the prophylaxis of cytomegalovirus (CMV) disease associated with solid organ transplantation, including kidney, lung, liver, pancreas, and heart. It contains high-titer CMV-specific IgG antibodies derived from pooled human plasma and is used to help reduce the risk of CMV infection in transplant recipients—especially when CMV-seropositive donor organs are transplanted into CMV-seronegative recipients. In non-kidney transplants involving CMV-seropositive donors and CMV-seronegative recipients (D+/R–), use of Cytogam® should be considered in combination with antiviral agents such as ganciclovir.

How Cytogam® Works:

• Provides passive immunity by delivering high concentrations of CMV-specific IgG antibodies
• Helps reduce the incidence and severity of CMV disease in high-risk transplant patients
• Supports immune defense during the vulnerable post-transplant period when antiviral immunity is compromised

FDA Approval:
Originally approved in 1998, Cytogam® remains FDA-approved for CMV prophylaxis in solid organ transplant recipients

For more information, please visit the Cytogam® patient website. Speak with your healthcare provider to determine if Cytogam® is the right treatment option for you.